Fierce Pharma

JUNE 3, 2023

The rising antibody-drug conjugate class has hit a setback as Seagen’s Adcetris, one of the earliest and fast-growing members of the group, was defeated by immune checkpoint inhibitor. | The rising antibody-drug conjugate class has hit a setback as Seagen’s Adcetris, one of the earliest and fast-growing members of the group, was defeated by immune checkpoint inhibitor in classical Hodgkin lymphoma.

248

248

Pharmacy Times

JUNE 3, 2023

Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.

Patients 52

Patients 52

Fierce Pharma

JUNE 3, 2023

After a recent data leak reveale | After a recent data leak revealed a dramatic benefit for J&J and Legend’s Carvykti in earlier treatment of multiple myeloma, the pair has peeled back some even more stunning efficacy results that could further pressure Bristol Myers Squibb’s rival CAR-T therapy, Abecma.

172

172

Pharmacy Times

JUNE 3, 2023

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

Manufacturing 49

Manufacturing Patients 49

Advertisement

Distribution

Pharmacy Times

JUNE 3, 2023

High tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades.

29

29

Pharmacy Times

JUNE 3, 2023

Identifying alterations in tumor genes has enabled medical oncologists to guide patients towards more specific therapies.

Medical 29

Medical Patients 29